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ABSTRACT
Immunotherapy for treatment of pancreatic ductal adenocarcinoma (PDAC) continues to
be an area of focus in the field of oncology. PDAC remains mostly incurable. The newest pillar
of cancer treatments, immunotherapy, provides promises to patients as a viable option. However,
the immunosuppressive microenvironment of PDAC tumors is one of the limitations on
treatment efficacy. Thus, it was strategized that reactivation of the tumor’s suppressive
microenvironment could lead to an increased efficacy of treatment. The use of an armed
oncolytic virus (OV) to infect the tumor has shown a potential to alter the tumor
microenvironment (TME) more effectively in comparison with its wildtype counterpart.
Vesicular stomatitis virus (VSV) was engineered to express Smac, (VSV-S), a protein found in
the intrinsic pathway of apoptosis. The ability of Smac to interact with the inhibitor of apoptosis
proteins (IAPs) makes VSV-S more effective in killing cancer cells. In addition, it was
determined that adapting the virus to the cell line by limited dilution increased VSV-S to
selectively target the murine cancer cell, KPC. Using a C57BL/6 mice model, subcutaneous
implanted KPC tumors were intratumorally injected with VSV-SKPC. After the infection by VSVS, tumor size was greatly reduced and the survival rate was greatly increased. In the infected
tumors, neutrophils were significantly increased, whereas macrophages were largely reduced,
especially immunosuppressive M2-macrophages. The overall TME was also more
immunologically active, which is proven by the reduced levels of cytokines and biomarkers
including TGF-𝛽, Arginase -1 and IL-10. This study indicates that the treatment of VSV-S was
successful in the reactivation of the immunosuppressive TME and inhibition of tumor growth.
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1
1.1

INTRODUCTION

Pancreatic Ductal Adenocarcinoma (PDAC) Background Significance
Pancreatic Ductal Adenocarcinoma (PDAC) has an average 5-year survival rate of less

than 10%; surgery is the only possible cure for the disease but the time of diagnosis is key for
successful results. For most patients, surgical removal of the tumor is not possible because the
early stages of the disease can easily be missed on a CT scan. This is due to the similar
attenuation between the diseased pancreas and a healthy pancreas. Approximately 30% of
patients with the disease present at late stages where the tumor has begun to metastasize. Aside
from the late stage diagnosis with PDAC, the disease is also lethal because of aggressive growth
and therapy resistance [1]. Moreover, other treatments such as chemotherapy have shown median
overall survival rates for late-term PDAC.
Combination of 5-fluoruracil (5-FU), leucovorin (LV), irinotecan, and oxaliplatin
(FOLFIRINOX) and gemcitabine-nab-paclitaxel has improved survival for patients with early
stages of the disease. However, a significant amount of trials with other combination therapies,
with the addition of drugs targeting new pathways, have yet to improvement cancer treatment.
Recently, novel immunotherapies have provided promising results in solid tumors such as
melanoma and renal cell carcinoma. Clinical success is due to the immune checkpoint inhibitors
and adoptive cell therapy activity in these cancer types. This new pillar of cancer treatment is
widely used to combat several types of diseases but immunotherapy-based treatment in PDAC
has yet to prove valuable. In clinical trials of anti-PD-L1 and anti-CTLA-4 antibodies, positive
responses were infrequent. This type of cancer has an immune-suppressive and therapy-resistant
microenvironment. To overcome these challenges, reactivation of the immunosuppressive tumor
microenvironment (TME) is an important approach [2].

2
1.2

The Tumor Microenvironment of PDAC
PDAC is far less accessible by immunotherapy for a multitude of reasons. One is the

stromal desmoplastic reaction where the cancer invasion induces new matrix formation by
activation of stromal cells. The invasion of epithelial tumor cells into the underlying connective
tissue stroma causes dynamic changes to its microenvironment (Figure 1.1). The reaction causes
negative regulation in immune responses and the immune suppressive tumor microenvironment
(TME) suppresses antitumor T cells with the infiltration of myeloid derived suppressive cells and
Treg cells. Activated antitumor T cells are also eliminated by PDAC directly in a process known
as “immune privilege” [3].
1.2.1

The Role of Immune Checkpoint Inhibitors

Figure 1.1: Suppressive and promotional components in the TME of Pancreatic cancer

The TME is a complex meshwork of extracellular matrix (ECM) macromolecules that are
filled with a collection of cells like cancer-associated fibroblasts (CAFs) [4]. Its presence in the
desmoplastic stroma in PDAC promote tumor growth, cell invasion and metastasis. The
immunosuppressive Treg cell, myeloid- derived suppressor cells and tumor-associated
macrophages (TAM) suppress the CD8+ T cells (Figure 1.1). Transforming growth factor- 𝛽
(TGF-𝛽), a highly pleiotropic cytokine, suppresses the T cell and promotes tumor growth.
Cytokine interleukin-10 (IL-10) promotes the CAFs that are responsible for metastasis, a
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prominent challenge in PDAC diagnosis. More devastatingly, an overexpression of arginase is a
poor prognostic factor in a wide variety of cancers, specifically PDAC. Since myeloid cells are
major contributors to immune defense against pathogens and play a role in tissue remodeling,
cells associated with strong immunosuppressive functions have been termed myeloid-derived
suppressor cells (MDSCs). These cells express high levels of arginase which, plays an opposite
role in immune response and is one of the main mechanism of immunosuppression. A reduction
in these levels has the potential to make the TME more immunologically active.
Anti-PD-1/PD-L1, immunotherapy treatments for advanced melanomas aim to block a
pathway that shields tumor cells from immune responses. Anti PD-1 is an immune checkpoint
inhibitor that activates tumor specific CD+ T cell responses. The antibody provides a new path
for therapy with emerging potential. The utilization of the antibodies have shown promising
results in clinical treatments. It also shows a correlation between the burden of tumor mutation
and CD8+ T cells with PD-1 and PD-L1 expression levels in the TME.
CD8+ T cells are a critical subpopulation of major histocompatibility complex class I
(MHC) restricted T cells and help mediate adaptive immunity [3]. Low expression of MHC-I
molecules makes it difficult to mark infected cells since foreign antigens present on the complex.
The lack of T cell immunity is the main reason the immune checkpoint blockade is
therapeutically ineffective in PDAC. Additionally, a reactionary immune response is a result of
the tumor antigenic strength. Hence, immunogenicity prediction by neoantigen quality metrics
shows a correlation to the survival of patients with the disease. To account for these challenging
conditions, a combination of chemotherapy or radiation with immunotherapy are in clinical trial
stages to determine viability.[4].
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Currently, a new therapy has been introduced as an option to improve the efficacy of
immunotherapy. Especially in combination with other successful treatments. The efficacy of
anti-PD-1 treatment was drastically enhanced with the combination of a oncolytic virus (OV), TVec (an engineered herpes virus), in clinical trials with breast cancer. The combination treatment
increased CD8+ T cells and heightened the PD-L1 protein expression level. Based on the success
of the trial utilizing OVs as an immunotherapy treatment, the potential to treat other more
difficult cancer types with a virus is promising [4].

1.3

The Promise of Oncolytic Viruses in Immunotherapy
One approach to exploit the immune system for cancer immunotherapies is to introduce a

OV to the tumor. Infection of the tumor by an OV has the potential to induce immune infiltration
to change the TME. Both the innate and adaptive immune systems are involved in cancer cell
immunosurveillance and destruction [5]. Changes in the TME of a solid tumor by an OV can
enhance the anti-tumor immunity and release neoantigens. Efficacy enhancements were observed
with the introduction of OVs in in vitro breast cancer studies. Cell viability, after 36 hours of
wild type vesicular stomatitis virus (wt VSV) infection, showed a decrease across several breast
cancer cell lines. The enhancements in the study demonstrate how the use of an OV has the
propensity to be a success option for treatment. The mechanism for introducing OVs to a TME
causes significant changes [5]. Infiltrating the TME causes changes that can alter the progression
of the tumor, since the condition of its microenvironment is key for its cell growth success.
Despite the clinical success some cases have experienced with reduction in tumor size and
ceased metastasis, ‘cold cancers’ remains resistant to a wide range of infections. By introducing
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a protein that induces adequate apoptosis with the OV, ‘cold cancers’ can dynamically be
changed to ‘hot cancers’ for successful immunotherapy treatment [6].
1.3.1

Benefits of Engineering VSV with Smac Protein

In a study using an EMT6 breast carcinoma model, wt VSV infection induced cytokine
and chemokine secretion which promoted CD8+ T cell tumor infiltration. The combination of the
OV with a Smac mimetic, LCL161, reinvigorated the exhausted CD8+ T cells and polarized the
tumor-associated macrophages (TAM) to the M1- like macrophages, which initiate immune
response[6]. The results of the oncolytic VSV infection to the EMT6 tumor suggest that the
effects could be enhanced if the microenvironment of the tumor is altered. Hence, a transgene
encoding Smac was inserted directly into the genome of VSV.

Figure 1.2: VSV and the insertion of a transgene between M and G nucleoproteins in the negative strand RNA
genome.

VSV is a negative RNA strand virus that has a broad cellular tropism. The receptor for
VSV is the low- density lipoprotein (LDL) and its homologs, which renders VSV’s ability to
infect a wide range of cells. The genome of VSV (Figure 1.2) is a single-strand RNA enwrapped
in the nucleocapsid. From the 30 end, there are five viral-encoded genes: N, P, M, G, and L
representing nucleocapsid, phosphoprotein, matrix, glycoprotein, and the L protein. The level of
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mRNA transcription decreases from N to L, with about 30% reduction compared to the
preceding gene [7].
The products of N, P, and M are required to be expressed proportionally for efficient viral
replication and assembly. So, the Smac transgene was inserted between M and G to allow for
expression after the viral replication was established. The multi-cycle growth curve of VSV-S
was compared to that of wt VSV. The final titer of VSV-S was similar to that of wt VSV, but its
growth rate was a little higher in the initial stage of infection. The average plaque size of VSV-S
infection was larger than that of wt VSV, which indicates that insertion of the Smac gene in VSV
genome between M and G did not compromise VSV growth in cell culture [7].
VSV-S, as a viral vector for Smac expression in tumor cells to induce adequate apoptosis,
is effective [8]. The second mitochondria-derived activator of caspase (SMAC) is a protein
associated with the mitochondrial outer membrane. Smac plays a key role in apoptosis pathways
by interacting with the inhibitor of apoptosis proteins (IAPs). During apoptotic stress, Smac in
the outer membrane of the mitochondria is released into the cytosol and mitigates the activities
of IAPs: cIAP1, cIAP2, XIAP, survivin, NAIP, ML-IAP and BRUCE. Once released by the
mitochondria, Smac interacts with various IAPs to release their inhibition of the intrinsic
apoptotic pathway by allowing caspase-9 and caspase-3 to be activated, shown in Figure 1.3 [9].
Smac mimetics (SMs) enhance apoptosis in a large number of difficult cancer cell lines. Thus, its
expression in VSV has the potential to change the TME to be more immunologically active.
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Figure 1.3 Intrinsic and extrinsic pathway of apoptosis

SMs can sensitize tumor cells to OVs and can greatly enhance the antitumor effects when
engineered together. In recent studies, the combination of Smac mimetic and an OV resulted in
synergistic enhancement for the infiltration of CD8+ T cells in immunosuppressed tumors [10].

Delivering Smac to the tumor cell by a viral vector, VSV, has the advantage to replicate
and spread in tumor cells to express at high levels. The pharmaceutical agent can offset the
upregulated expression of IAPs in tumor cells while the proteins biological functions remain
consistent in comparison to being recapitulated in SMs. SMs are substrates of p-glycoprotein
whom are subject to efflux via the multidrug resistance mechanism [11]. By encoding Smac into
the genome of VSV, efflux by the p-glycoprotein can be eliminate as a concern. Moreover, the
infection by VSV itself will trigger apoptosis, which will be synergetic with the antitumor activity
of Smac. The armed OV has the potential to alter the TME more effectively in comparison with
its wildtype counterpart. The ability of Smac to interact with IAPs makes VSV-S more effective
in killing cancer cells. This generation of VSV-S was constructed via reverse genetics, as stated
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previously. The transgene of Smac was cloned in the VSV genome in the cDNA vector.
Lipofectamine (Thermo Fisher Scientific) co-transfection of the VSV-S cDNA with plasmid-N
(pN), plasmid-P (pP), and plasmid-L (pL) into BSR cells infected with vaccinia virus expressing
T7 RNA polymerase, vTF7-3, rescued VSV-S. Vectors pN, pP, and pL express the nucleocapsid,
phosphoprotein, and the L protein, respectively [12]. The rescue of wt VSV by reverse genetics
was also made possible by using the wild-type (WT) genomic cDNA.
2
2.1

EXPERIMENTATION

Adaptation of Murine KPC to VSV-S by Limited Dilution

To strengthen the infectivity targeting PDAC cells, the virus was adapted via limited dilution.
VSV-S was adapted to a pancreatic cancer cell line, KPC, that was derived from the KrasG12D;
Trp53R172H; Pdx1-Cre (KPC) mouse model. Adaptation allows the virus to evolve through a
series of passages either in cell culture or in an animal host [12]. A stock of VSV-S was prepped
by infecting HeLa cells, a cervical cancer cell line.
In the infected HeLa cell culture medium, the titer of VSV-S was 1.5+0.15x106 PFU/mL,
outlined in Table 2.1. A set of VSV-S inocula was prepared by 10-fold serial dilution (10-1 to 106).

The virus inocula was added to different wells of KPC cells; the strategy is shown in Figure

2.1. The same method was also carried out with a wt VSV that expresses a viral P protein fused
with mCherry. In the next passage, the virus inoculum is picked from the infected well that has
been inoculated with the lowest dilution of virus samples, judged by the same cytopathogenic
effect (CPE) as cells infected with fluorescent wt VSV. After 5 passages, the adapted VSV-S is
plaque purified twice and is labeled as VSV-SKPC. The titers of VSV-SKPC are determined by
plaque assays (PFU) in HeLa cells, and TCID50 in KPC cells in triplets. In adaptation of VSV-S
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to KPC, 3 passages are necessary to reach the high limit, and then 2 more passages were carried
out. A comparison of VSV-SKPC versus VSV-S titers are summarized in Table 2.1. Based on the
data, the adaptation by limited dilution increased the infectivity of VSV-S in KPC cells by 20-fold.
The cytopathogenic effect (CPE) was examined under a microscope 24 hour post-infection. The
dilution at which KPC cells were effectively infected by VSV-S was selected based on the level
of CPE that was the same for the fluorescent wt VSV.
Table 2.1: Titers of Adapted VSV-S

VSV-SKPC

VSV-S

PFU/mL (HeLa)

3.3±0.7x107

1.5±0.15x106

TCID50 (KPC)

6.3±1.1x107

3.4±0.6x106

Evolutionary mutations in
the serial passages occur,
causing the newly
emerged virus to prefer infection in the specific cell; which is a remarkable capability of the OV.

Figure 2.1 Demonstration of Adaptation by Limited Dilution

To demonstrate the adapted OVs ability to treat the difficult tumor in succession, in vivo
studies were conducted. Tumor treatment included intratumorally injections of VSV-SKPC several
days after subcutaneous implantation of 0.5 x 106 KPC_luc cells on the left flank. The tumors
were injected in both male and female C57BL/6 models. Since VSV- SKPC has an increased
infectivity of KPC cells, the virus was propagated in KPC cells prior to infection.
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2.2

Growth and Concentration of VSV-SKPC
The pancreatic cancer cell line of interest, KPC, was cultured and infected with VSV-S for

the study using the C57BL/6 model. KPC cells were grown in DMEM with penicillin and
streptomycin, supplemented with 10% fetal bovine serum (FBS). Cells were split onto several
150 mm in diameter plates and incubated until they grew to confluence. After approximately 24
hours, the culture media was removed via suction and the cells were washed once with warm
Dulbecco's phosphate-buffered saline (DPBS) to remove the old media. To infect the cells with
VSV-S, 1 mL of DMEM++PS absent of FBS was added to each plate along with 100 uL of the
engineered OV. Cells were infected at MOI =0.1. The cells were incubated for an hour with
constant rotation, to ensure all cells were infected. An additional 12 mL of media was added to
the plates and the infected cells were harvested for 24-48 hours.
The supernatants from infected cells were clarified and then concentrated into pellets via
ultracentrifugation (Beckman Coulter). After clarification at low speed centrifugation, the
centrifugation tubes containing the cleared supernatant were allowed to spin at 16100 RPM at 4
°C for 2 ½ hours using a 45 Ti fixed-angle titanium rotor. The media was discarded and the
pellets were then resuspended with 5% sucrose in phosphate buffer solution PBS, stirred and
pipetted into an 1 mL cryptogenic tube with a total volume of 0.5 mL. Several cryptogenic tubes
were collected and stored in liquid nitrogen for later use.
2.3

Plaque Assay and Calculation of Titers
Calculating the plaque forming units, data shown in Table 2.1, was essential for counting

the numbers of viruses present in the selected dilution. In the table, data comparisons between
the wildtype VSV and the adapted virus is shown for plaque assay and TCID50 calculation.
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Overall, the titer for the adapted VSV was higher than its predecessor. Thus, the selective
infectivity was increased.
To preform plaque assay, serial dilutions of the virus stock were completed using a
similar strategy to Figure 2.1. Wells of monolayer KPC cells were infected with 0.5 mL of virus
inoculum, incubated for 1 h at 37 °C, 5% CO2, and a layer of 0.8% Seaplaque agarose, a
nutrient-rich medium, was added to each well. The plate was incubated for 48 h at 37 °C, 5%
CO2, after the gel was allowed to form in each well. The infected cells released a viral progeny.
The gel prohibited the spread of the virus and resulted in a plaque, which is a circular virus zone.
A dye was then utilized to develop contrast between the living cells and the plaques. The well
with a significant amount of plaques, between 10 – 100 were counted exactly. Based on the virus
stock dilution used, 10-1-10-7, the dilution was multiplied by the volume of virus added to the
well and the number of plaques were divided by that product. The equation:
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑃𝐹𝑈
(𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛)(𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 𝑣𝑖𝑟𝑢𝑠 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑤𝑒𝑙𝑙)

𝑚𝐿

=

was used for the plaque assay calculation for KPC

adapted VSV-S and its wildtype, which are shown in Table 2.1.

3

𝑃𝐹𝑈

RESULTS
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Figure 3.1: Size of KPC_luc Tumor in C57BL/6 Male Models with Black Line Representing the Control Mice
and Red Line Representing Treated Mice. Blue Arrow Represents Days of Injection of Anti-PD-1 and Black
Arrows Represent Injection of VSV-SKPC

The C57BL/6 male mice were injected with 0.5x106 KPC_Luc cells subcutaneously on
the left flank. The size of tumors was monitored by luciferase activities using an IVIS imager.
On Days 0, 2 and 4, indicated by the black arrows, 3.0x107 PFU of KPC adapted VSV-S was
intratumorally injected in each mouse. On Day 12, indicated by the blue arrow, 40 µg of mouse
anti-PD-1 (BioXcell) was intratumorally injected in each mouse. The red line on the figure
represents the average of the five mice. Intratumorally injection of phosphate buffer solution
PBS was carried out in two control mice also indicated by the black arrows (Figure 3.1).
Similarly, the C57BL/6 female mice were injected with 0.5x106 KPC_Luc cells
subcutaneously. The size of tumors was again monitored by luciferase activities using an IVIS
imager. On Days 0, 2 and 4, indicated by the black arrows, 3.0x107 PFU of KPC adapted VSV-S
was intratumorally injected in each mouse. On Days 6 and 12, indicated by the blue arrows, 40 µg
of mouse anti-PD-1 (BioXcell) was intratumorally injected in each mouse. Mice 1 and 2 were
euthanized on Day 10 and 12, respectively. The red line represents the average of the three
surviving mice (Figure 3.2). From the graph, its certain that the control mice tumors were able to
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grow exponentially without the adapted VSV-S treatment. The tumor that received the treatment
were able to experience complete regression. A remarkable achievement for the immunotherapy
treatment. In comparison to the trajectory of the male tumors, it is clear that the female models
work better with the treatment. The immune response variance between genders is an important
factor to consider and examine.

Figure 3.2: Size of Tumor in C57BL/6 Male Models; Black Line Representing the Control Mice and Red Line
Representing Treated Mice. Blue Arrow Represents Days of Injection of Anti-PD-1 and Black Arrows
Represent Injection of VSV-SKPC

To directly confirm the selective infectivity, infection of KPC and MS1 cells by adapted
VSV-S were compared by their CC50 values measured with MTT assays shown in Figure 3.3A.
The selectivity is 94 -fold for KPC cells over MS1 cells. These results demonstrated that VSV-S
adaptation by limited dilution is readily applicable to target cancer cells in a very short period of
time, usually a few days [14]. To confirm that adaptation by limited dilution increases selective
infection by VSV-SKPC, mouse KPC and MS1 cells (pancreatic islet endothelial cell line, ATCC)
were infected with VSV-SKPC and wt VSV at different MOIs in Figure 3.3A. KPC cells could be
effectively infected by wt VSV at MOI=0.1, and MS1 cells, at MOI=1. On the other hand, KPC
cells could be effectively infected by VSV-SKPC at MOI=0.01, and MS1 cells, at MOI=10. The
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selective ratio is 10:1 (KPC:MS1) for wt VSV based on CC50 measured by MTT assays, whereas
the selective ratio is 94:1 (KPC:MS1) for VSV-SKPC. Based on this comparison, selective infection
of VSV-S was increased by adaptation by limited infection.

Figure 3.3: A. KPC and MS1 cells: pancreatic islet endothelial cell line ATCC, infected with VSV-SKPC and wt
VSV. MS1 infected with VSV-SKPC at MOI=10, wt VSV at MOI=1.0 and KPC infected with VSV-SKPC at
MOI=0.01, wt VSV at MOI=0.1. B. Selective ratio is 10:1 (KPC:MS1) for wt VSV and 94:1 (KPC:MS1) for
VSV-SKPC.

3.1

TME Changes Induced by Adapted VSV-S
The KPC_luc tumor samples were collected on day 2 and 8, after the second injection of

VSV-S or PBS control. Shown in Figure 3.4 and 3.5 the total amounts of leucocytes (CD45+) in
tumor samples were increased by 3-3.5-fold with VSV-S treatment, compared to the control,
after 8 days. Yet, the ratio between lymphocytes and myeloid cells, or CD8+ and CD4+ T cells,
was not changed significantly despite that the total number of lymphocytes greatly increased.
Mainly, changes in the myeloid cells largely increased neutrophil populations, and decreased
macrophages, which was obvious just 2 days after VSV-S treatment, with the decrease of
macrophages being more visible. Indicating that treatment with VSV-S caused strong
inflammation in the tumors and largely increased tumor infiltrating lymphocytes (TIL) [15].
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Figure 3.4: Tumor microenvironment (TME) analysis. (i) Flow cytometry of isolated male and female tumor
cells after 2 days of treatment with intratumoral injection of VSV-S or control PBS. Gates and biomarkers are
labelled.

The populations of M2 versus M1 macrophages were compared during a large reduction in
macrophage population to access the immunosuppressive TME regression. Significant reductions
of M2 macrophages (CD206+) were observed just 8 days after VSV-S treatment, with significant
reductions 2 days after VSV-S treatment. The populations of M1 macrophages (CD86+) were also
reduced, which is potentially the result of significant reductions in the total number of
macrophages. In all, these observations suggest that the VSV-S treatment could alter the
immunosuppressive TME.
The large increase of neutrophils in tumors could cause more death of cancer cells due to
innate immunity [16]. Several studies confirmed that neutrophils participate in tumor cell clearance
upon OV infection of tumors [16-18], which is also consistent with the results of efficacious tumor
regression by VSV-S treatment of breast cancer xenografts [3].
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Figure 3.5: Tumor microenvironment (TME) analysis. (i) Flow cytometry of isolated male and female tumor
cells after 8 days of treatment with intratumoral injection of VSV-S or control PBS. Gates and biomarkers are
labelled.

More importantly, treatment with an OV altered the TME which in turn enhanced the efficacy
of this immunotherapy treatment. This advantage is illustrated by more than 3-fold changes of
leucocytes in the tumors infected by VSV-S. The change was noticeable after day 2, and more
obvious after 8 days, during the final VSV-S infection. Even though the total number of
lymphocytes was greatly increased, the ratio between lymphocytes and myeloid cells, or between
CD8+ and CD4+ T cells, however, was not changed significantly.
The most important changes of myeloid cells are the dramatic increase of neutrophils, and the
decrease of macrophages. These changes are consistent with strong inflammation in the tumor
caused by VSV-S infection. Neutrophils exhibit tumor suppressive activities by generating
reactive oxygen species (ROS), activation of the IFN-γ pathway, and up-regulation of antigen
presentation [16]. The immunosuppressive TME was most likely reverted by the large reduction
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of M2-like macrophages. Based on the date summarized in Figures 3.1 and 3.2, it is clear that
treatment with VSV-S caused strong inflammation in the tumors and largely increased tumor
infiltrating lymphocytes (TIL) [17].

Figure 3.6: C57BL/6 Female Tumor by Luciferin on the Initial day of Injection of VSV-SKPC, Day 7 and Day
19

After subcutaneous implantation of KPC-luc cells, the tumors were monitored with IVIS
imagining. When tumors became visible, the size was measured as the integrated luciferase activity
detailed in Figure 3.6. On Days 0, 2, and 4, 3.0X107 PFU of VSV-SKPC in 30 µL was intratumorally
injected in each mouse, and tumor growth was recorded every 2 days till Day 22. The controls
used 30 µL of PBS and intratumorally injected it into the tumor on the same days. On Day 12, 40
µg of anti-PD-1 antibody was intratumorally injected in each of the VSV-SKPC treated mice. The
quantitation was determined to be 4.5x106 U/g of tumor mass.
VSV-S treatment was able to inhibit the tumor growth rate in comparison to the control
(p<0.0006). Mostly, VSV-S treatment effectively arrested tumor growth. With a followed-up
treatment of anti-PD-1 antibody, the tumor was able to completely regress. Yet, complete
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regression of the tumor was not achieved in some cases highlighted in Figure 3.6, case 2. However,
obvious inhibition of tumor growth by VSV-S treatment was observed with a follow-up treatment
of anti-PD-1 antibody. The best outcome for the combination treatment with VSV-S and anti-PD1 antibody, was the survival of the tumor bearing mice was increased. The median time to death
(MTD) was doubled to >27.4 days in comparison to MTD of 14.9 days for the control group. There
was also interesting differences in tumor growth were found between female and male mice,
(Figure 3.1 and Figure 3.2) which sparked interest in the immune response variance between the
sexes. The tumor growth rate is faster in male than in female mice, with or without treatment with
VSV-S.

Figure 3.7: IHC Staining Results For PDAC of Cytokine IL-10 Expression in C57Bl/6 Model, A. Female 10
days; B. Female 20 days; C. Female treated 10 days; D. Female treated 20 days; E. Male 10 days; F. Male 20
days; G. Male treated 10 days; H. Male treated 20 days.

The large increase of neutrophils in tumors could cause more death of cancer cells due to
innate immunity [18]. Several studies confirmed that neutrophils participated in tumor cell
clearance upon OV infection of tumors[19-22], which is also consistent with our previous results
of efficacious tumor regression by VSV-S treatment of breast cancer xenografts [22].
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3.2

Immunohistochemistry Results

The changes to the TME due to VSV-S treatment are examined in depth using
immunohistochemistry staining of the paraffin-embedded tumor tissues. Immunosuppressive
factors argenase1 (ARG1), interleukin 10 (IL-10), and transforming growth factor-beta (TGF-β)
were significantly decreased in both male and female mice, which indicates that the VSV-S
treatment could reduce the immunosuppressive effect in the TME (Figure 3.7). The PD-L1
expression level also decreased after the treatment, shown in Figure 3.7. Typically, the expression
of PD-L1 increases in the tumor to down-regulate the ongoing immune activation. This mechanism
allows the expression of PD-L1 on tumor cells to inhibit local anti-tumor T cell responses [15].
However, the increased expression of tumor PD-L1 was mostly in myeloid cells [16]. The
observed decrease of PD-L1 expression after VSV-S treatment may be associated with changes in
myeloid cells.
The considerable reduction of macrophages, especially M2-like macrophages, most likely
were related to reverting the immunosuppressive TME. To confirm this notion, levels of arginase
1 (ARG1), TGF-, and IL-10 in KPC tumors were analyzed by immunohistochemistry before and
after treatment, shown in Figure 3.7. It was observed that the optical density of the treated tumors,
shown in gray, had decreased levels of arginase 1, TGF- β, PD-L-1, and IL-10. This indicates that
the TME is altered with the infection of adapted VSV-S. Cells associated with vital
immunosuppressive functions are known as myeloid-derived suppressor cells (MDSCs), which
express arginase. Arginase plays an opposite role in immune response and is one of the primary
mechanisms of immunosuppression [22], so a decrease in its levels is desired. MDSCs also express
suppressive cytokines like TGF-β and IL-10 in the tumor. The changes made in the
immunosuppressive TME by VSV-S infection of the tumor reveal a correlation. The observed
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reduction in PD-L1 may be associated with its decline in myeloid cells, not necessarily PD-L1
expressed in tumor cells. Extended regression of tumors can be achieved by combination regimens
of OV treatment and immunotherapy.
4
4.1

DISCUSSION

Evaluate antitumor applications of VSV-SKPC in the syngeneic model for pancreatic
cancer
Tumor-associated macrophages (TAM) play an essential role in the processes of tumor

carcinogenesis, including the escape of cancer cells from the tumor into the circulation and the
suppression of antitumor immune functions and drug resistance. Univariate analysis showed that
worse overall patient survival was significantly associated with high CD59 expression in the
tumor tissues. Therefore, overexpression of CD59 may be a biomarker indicating worse survival
for pancreatic cancer patients. The data suggest that CD59 expression is proportional to the TAM
infiltration in pancreatic cancer tissues. There is likely cross-talk and cooperation between TAMs
and CD59 expression in pancreatic cancer cells [20].
The ultimate application of VSV-S or its derivatives is to enhance treatment efficacy for
PDAC and other cancers. As mentioned previously, KPC tumors were implanted under the skin
of both male and female C57BL/6 models. The adapted VSV-S was used as treatment with the
combination of anti-PD-1. It was determined from the study that treatment with the anti-PD-1
antibody, after 8 days of the virus injection, prolonged inhibition of tumor growth and even
helped to eliminate the tumor in the female models (3 out of 8 female mice, and 2 out of 8 male
mice). As previously reported, anti-PD-1 antibodies alone cannot change the tumor growth or
survival in KPC mouse models. Combination therapies only increased survival. The delayed
administration of the immune checkpoint inhibitor combined with the OV is consistent with the
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temporal change of the TME [25]. The combination therapy significantly extended the survival
of tumor-bearing mice.

4.2

Immune Response Variance Between Male and Female Models
There are two observations in the study that are fascinating. First, the growth rate of tumors

in female mice after treatment was significantly slower than in male mice. The responses are also
more favorable in female mice versus male mice. This observation was consistent with patient
incident case numbers, and deaths which peaked at the ages of 65–69 years for males and 75–79
years for females [25]. PDAC appears to be more lethal to males in comparison to females. Data
suggests that female patients may respond better to immunotherapy and have a better chance of
survival. Secondly, the efficacy of the treatment with the OV appeared to be dependent on the
initial tumor size when treatment began. This dependence is due to the degree of virus spread
within the tumor mass. When the tumor size is smaller, it is expected that a higher portion of the
mass is directly exposed to the infection upon injection. Tumor growth in the male models was
reportedly faster than the females. To study cell-cell interaction in the TME, spatial information
at the resolution of a single cell is essential, and a microscopy is the most helpful tool to obtain
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Figure 4.1: The tumor growth curves of treated female mice (n=3) (pink) and male mice (n=3) (blue)
groups. Tumor size was presented as logarithm values of the luciferase activity measured on an IVIS imager.
Error bars represent the standard deviations. Treatment regimen was intratumoral injection of 3.0 x107 PFU of
VSV-SKPC on Days 0, 2 and 4, and 40 µg of anti-PD-1 antibody on Day 12.

The immune response variation between sexes has notable differences. Females are
parasitized less often than men, with male immune systems having a lesser ability to fight off
pathogens. Females usually have a more robust immune response, which is not always positive.
Often this makes them more susceptible to immunopathology such as autoimmunity compared to
males. This susceptibility to autoimmune disease has been associated with immune response
components such as particular gene variants at the major histocompatibility complex (MHC).
MHC was central to the adaptive immune response; a set of highly polymorphic genes encodes
these molecules. High diversity of MHC gene variants has been theorized to be beneficial; this
may be due to the ability to recognize a broader range of pathogens or the increased chance of
carrying advantageous genes that maximize disease resistance [18].
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5

CONCLUSION/ SIGNIFCANCE

Immunotherapy treatment for PDAC using oncolytic viruses and immune checkpoint
inhibitors is a promising approach. However, many challenges remain within the method as
some tumors are resistant to infection and fail to respond to the inhibitors adequately. The
efficacy of VSV-S was enhanced in previous in vivo studies, with several breast cancer cell lines,
compared to its wildtype counterpart. Infection was more extensive by VSV-S, especially for the
T-47D cell line, which expresses very high levels of XIAP. To summarize the results from the
infection of PDAC, adaption of the virus and increasing infectivity allow treatment to overcome
the obstacles mentioned.
The activation of caspase-9 and caspase-3 from the intrinsic pathway of apoptosis resulted
from the infection of VSV-S. The activation was made possible by inserting a transgene-like
Smac in the genome of VSV. The study with PDAC demonstrated the effectivity of VSV-S with
a immunologically ‘cold cancer’. Pancreatic ductal adenocarcinoma has shown therapy
resistance with other therapy methods but adapted VSV-S can overcome this difficulty. In cases
with the female models, the KPC tumors experienced a complete regression which is an
impressive result for this specific cancer cell line. The overall significance of the PDAC study
demonstrated how the efficacy of VSV-S was enhanced by adaption to the cancer cell line.
Moreover, by increasing the infectivity of the OV to its target tumor, regression or complete
inhibition of the tumor is possible.
The use of an armed OV suggests that improvements in immunotherapy treatments for
PDAC are achievable. The methods discussed can turn the disease from immunologically “cold”
to immunologically “hot.” The therapy by immune checkpoint blockade was especially
promising. Treatment with VSV-S has advantages over other immunotherapy treatment options.
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VSV has a high mutation rate, and the virus can be adapted to the specific cell line to increase
infectivity considerably (e.g., 20-fold in mouse KPC cells). Using an OV, infection of tumor
cells can initiate inflammatory responses in the TME and release many tumor antigens to evoke
anti-tumor immunity.
Combining treatments with chemotherapy medication and immunotherapy is tolerable but
not overly conclusive as a viable option. From the IHC staining, a change in the TME was
observed. A decrease in the optical density of several markers, which contribute to the
suppressive TME of PDAC, was witnessed. In the infected tumors, neutrophils were
significantly increased, whereas macrophages were primarily reduced, especially
immunosuppressive M2 macrophages. These changes are consistent with strong inflammation in
the tumor caused by VSV-S infection. The overall TME was also more immunologically active,
proven by the reduced levels of cytokines and biomarkers, including TGF-𝛽, Arginase -1, and
IL-10. To conclude, VSV-S successfully activated the immunosuppressive TME and inhibited
tumor growth in pancreatic cancer.
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